Concepedia

Peiguo Cao

PC

Statistics

Publications

42

Citations

2.9K

H-Index

25

Active since

2011

Affiliations

Central South University(Current)

Third Xiangya Hospital

Hunan Cancer Hospital

Zhejiang Cancer Hospital

Sun Yat-sen University

Peiguo Cao is an author at Central South University specializing in oncology, medicine, and molecular oncology.

ORCID

Publications per year

2011–2025

42

Publications

42

Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer

Ying Cheng, Liang Han, Lin Wu et al. · JAMA · 2022 · 456 citations · Full text

, , +17

Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

Josep M. Llovet, Masatoshi Kudo, Philippe Merle et al. · The Lancet Oncology · 2023 · 421 citations · Full text

, , +12

Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer

Jin Li, Shukui Qin, Rui‐Hua Xu et al. · JAMA · 2018 · 404 citations · Full text

, , +17

Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial

Shengxiang Ren, Jianhua Chen, Xingxiang Xu et al. · Journal of Thoracic Oncology · 2021 · 313 citations

, , +6

miR-33a functions as a tumor suppressor in melanoma by targeting HIF-1α

Jianda Zhou, Dan Xu, Huiqing Xie et al. · Cancer Biology & Therapy · 2015 · 99 citations · Full text

, , +15

1–5 of 42